The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)

(2017) Peng Zhan et al.   Recent Patents on Anti-Cancer Drug Discovery

A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway

(2016) Jung Min Song et al.   JOURNAL OF ALZHEIMERS DISEASE

Inhibition of Histone Deacetylase 3 Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons

(2016) Kumar Krishna et al.   JOURNAL OF ALZHEIMERS DISEASE

A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice

(2016) Mar Cuadrado-Tejedor et al.   NEUROPSYCHOPHARMACOLOGY

HDAC inhibitor–dependent transcriptome and memory reinstatement in cognitive decline models

(2015) Eva Benito et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue

(2015) Gavin Rumbaugh et al.   NEUROPSYCHOPHARMACOLOGY

Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion

(2015) Hui Liu et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Target engagement and drug residence time can be observed in living cells with BRET

(2015) Matthew B. Robers et al.   Nature Communications

Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

(2015) M. Cuadrado-Tejedor et al.   Clinical Epigenetics

The Aβ-clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain

(2014) Caroline Kerridge et al.   JOURNAL OF NEUROCHEMISTRY

Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

(2014) Andre Fischer   NEUROPHARMACOLOGY

Age-dependent effects of valproic acid in Alzheimer’s disease (AD) mice are associated with nerve growth factor (NGF) regulation

(2014) H. Noh et al.   NEUROSCIENCE

The Anti-Tumor Histone Deacetylase Inhibitor SAHA and the Natural Flavonoid Curcumin Exhibit Synergistic Neuroprotection against Amyloid-Beta Toxicity

(2014) Jia Meng et al.   PLoS One

The Potential of HDAC Inhibitors as Cognitive Enhancers

(2013) Johannes Gräff et al.   Annual Review of Pharmacology and Toxicology

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance

(2013) Casey Cook et al.   HUMAN MOLECULAR GENETICS

Oral Administration of Histone Deacetylase Inhibitor MS-275 Ameliorates Neuroinflammation and Cerebral Amyloidosis and Improves Behavior in a Mouse Model

(2013) Zhi-Yuan Zhang et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus

(2012) Zhi-Gang Yao et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease

(2012) Nambirajan Govindarajan et al.   EMBO Molecular Medicine

Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

(2012) You Me Sung et al.   EXPERIMENTAL NEUROLOGY

Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation

(2012) Casey Cook et al.   HUMAN MOLECULAR GENETICS

HDAC6 Inhibitor Blocks Amyloid Beta-Induced Impairment of Mitochondrial Transport in Hippocampal Neurons

(2012) Chaeyoung Kim et al.   PLoS One

Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders

(2012) Zacharoula Konsoula et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Brain plasticity, memory and neurological disorders: an epigenetic perspective

(2010) Gabrielle A. Lockett et al.   NEUROREPORT

Liquiritigenin inhibits Aβ25–35-induced neurotoxicity and secretion of Aβ1–40 in rat hippocampal neurons

(2009) Rui-ting Liu et al.   ACTA PHARMACOLOGICA SINICA

Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise

(2009) Antonello Mai et al.   CURRENT PHARMACEUTICAL DESIGN

Synergistic drug combinations tend to improve therapeutically relevant selectivity

(2009) Joseph Lehár et al.   NATURE BIOTECHNOLOGY

Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease

(2009) Mark Kilgore et al.   NEUROPSYCHOPHARMACOLOGY

Histone deacetylase inhibitors: possible implications for neurodegenerative disorders

(2008) Eric Hahnen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS